Liang J. Tan

8A Biomedical Grove, Immunos, Level 5
Singapore, 138648, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult.

Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult.

Journal: Brain pathology (Zurich, Switzerland)

Published: September 16, 2021

Haploinsufficiency of CYP8B1 associates with increased insulin sensitivity in humans.

Haploinsufficiency of CYP8B1 associates with increased insulin sensitivity in humans.

Journal: The Journal of clinical investigation

Published: July 06, 2021

Impaired Remyelination in a Mouse Model of Huntington Disease.

Impaired Remyelination in a Mouse Model of Huntington Disease.

Journal: Molecular neurobiology

Published: February 06, 2019

Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.

Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.

Journal: Molecular neurobiology

Published: September 05, 2018

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.

Journal: Molecular neurodegeneration

Published: April 09, 2018

Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model.

Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model.

Journal: NMR in biomedicine

Published: January 24, 2018

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Journal: JCI insight

Published: July 05, 2017

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Journal: Scientific reports

Published: February 03, 2016

Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease.

Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease.

Journal: Human molecular genetics

Published: December 24, 2015

Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.

Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.

Journal: Experimental neurology

Published: October 10, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026